Ian Collins

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6292556/publications.pdf

Version: 2024-02-01

65 papers	4,248 citations	147801 31 h-index	114465 63 g-index
71 all docs	71 docs citations	71 times ranked	6791 citing authors

#	Article	IF	Citations
1	4,5-Diarylisoxazole Hsp90 Chaperone Inhibitors: Potential Therapeutic Agents for the Treatment of Cancer. Journal of Medicinal Chemistry, 2008, 51, 196-218.	6.4	386
2	Macrocycles in new drug discovery. Future Medicinal Chemistry, 2012, 4, 1409-1438.	2.3	362
3	New approaches to molecular cancer therapeutics. Nature Chemical Biology, 2006, 2, 689-700.	8.0	361
4	CHK2 kinase: cancer susceptibility and cancer therapy â€“ two sides of the same coin?. Nature Reviews Cancer, 2007, 7, 925-936.	28.4	266
5	Probing the Probes: Fitness Factors For Small Molecule Tools. Chemistry and Biology, 2010, 17, 561-577.	6.0	253
6	Structure of the Ire1 autophosphorylation complex and implications for the unfolded protein response. EMBO Journal, 2011, 30, 894-905.	7.8	201
7	Targeting the cell division cycle in cancer: CDK and cell cycle checkpoint kinase inhibitors. Current Opinion in Pharmacology, 2005, 5, 366-373.	3.5	195
8	Anticancer therapy with checkpoint inhibitors: what, where and when?. Trends in Pharmacological Sciences, 2011, 32, 308-316.	8.7	187
9	Measuring and interpreting the selectivity of protein kinase inhibitors. Journal of Chemical Biology, 2009, 2, 131-151.	2.2	151
10	Chemical approaches to targeted protein degradation through modulation of the ubiquitinâ€“proteasome pathway. Biochemical Journal, 2017, 474, 1127-1147.	3.7	122
11	CCT241533 Is a Potent and Selective Inhibitor of CHK2 that Potentiates the Cytotoxicity of PARP Inhibitors. Cancer Research, 2011, 71, 463-472.	0.9	96
12	Identification of 4-(4-Aminopiperidin-1-yl)-7H-pyrrolo[2,3-d]pyrimidines as Selective Inhibitors of Protein Kinase B through Fragment Elaboration. Journal of Medicinal Chemistry, 2008, 51, 2147-2157.	6.4	93
13	CCT244747 Is a Novel Potent and Selective CHK1 Inhibitor with Oral Efficacy Alone and in Combination with Genotoxic Anticancer Drugs. Clinical Cancer Research, 2012, 18, 5650-5661.	7.0	84
14	Demonstrating In-Cell Target Engagement Using a Pirin Protein Degradation Probe (CCT367766). Journal of Medicinal Chemistry, 2018, 61, 918-933.	6.4	81
15	A Structural Comparison of Inhibitor Binding to PKB, PKA and PKA-PKB Chimera. Journal of Molecular Biology, 2007, 367, 882-894.	4.2	80
16	The Preclinical Pharmacology and Therapeutic Activity of the Novel CHK1 Inhibitor SAR-020106. Molecular Cancer Therapeutics, 2010, 9, 89-100.	4.1	77
17	Discovery of 4-Amino-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamides As Selective, Orally Active Inhibitors of Protein Kinase B (Akt). Journal of Medicinal Chemistry, 2010, 53, 2239-2249.	6.4	68
18	Aminopyrazine Inhibitors Binding to an Unusual Inactive Conformation of the Mitotic Kinase Nek2: SAR and Structural Characterization. Journal of Medicinal Chemistry, 2010, 53, 7682-7698.	6.4	63

#	Article	IF	Citations
19	Rapid Evolution of 6-Phenylpurine Inhibitors of Protein Kinase B through Structure-Based Design. Journal of Medicinal Chemistry, 2007, 50, 2289-2292.	6.4	58
20	Structure-based design, discovery and development of checkpoint kinase inhibitors as potential anticancer therapies. Expert Opinion on Drug Discovery, 2013, 8, 621-640.	5.0	57
21	The clinical development candidate CCT245737 is an orally active CHK1 inhibitor with preclinical activity in RAS mutant NSCLC and Eî¼-MYC driven B-cell lymphoma. Oncotarget, 2016, 7, 2329-2342.	1.8	56
22	Identification and characterisation of 2-aminopyridine inhibitors of checkpoint kinase 2. Bioorganic and Medicinal Chemistry, 2010, 18, 707-718.	3.0	50
23	Molecular mechanisms of human IRE1 activation through dimerization and ligand binding. Oncotarget, 2015, 6, 13019-13035.	1.8	49
24	Structure-Based Design of Potent and Selective 2-(Quinazolin-2-yl)phenol Inhibitors of Checkpoint Kinase 2. Journal of Medicinal Chemistry, 2011, 54, 580-590.	6.4	46
25	Structure-based design of isoquinoline-5-sulfonamide inhibitors of protein kinase B. Bioorganic and Medicinal Chemistry, 2006, 14, 1255-1273.	3.0	40
26	Target 2035 â€“ update on the quest for a probe for every protein. RSC Medicinal Chemistry, 2022, 13, 13-21.	3.9	39
27	The 2,11-Cyclized Cembranoids: Cladiellins, Asbestinins, and Briarellins (Period 1998â€“2010). Journal of Natural Products, 2011, 74, 2318-2328.	3.0	38
28	CHK1 Inhibition Is Synthetically Lethal with Loss of B-Family DNA Polymerase Function in Human Lung and Colorectal Cancer Cells. Cancer Research, 2020, 80, 1735-1747.	0.9	38
29	A critical evaluation of the approaches to targeted protein degradation for drug discovery. Drug Discovery Today: Technologies, 2019, 31, 5-13.	4.0	37
30	Identification of Inhibitors of Checkpoint Kinase 1 through Template Screening. Journal of Medicinal Chemistry, 2009, 52, 4810-4819.	6.4	36
31	Design and Development of Signal Transduction Inhibitors for Cancer Treatment: Experience and Challenges with Kinase Targets. Current Signal Transduction Therapy, 2006, 1, 13-23.	0.5	35
32	Identification of Small-Molecule Inhibitors of Protein Kinase B (PKB/AKT) in an AlphaScreenâ„¢ High-Throughput Screen. Journal of Biomolecular Screening, 2006, 11, 822-827.	2.6	30
33	Identification by High-Throughput Screening of Viridin Analogs as Biochemical and Cell-Based Inhibitors of the Cell Cycleâ€“Regulated Nek2 Kinase. Journal of Biomolecular Screening, 2010, 15, 918-927.	2.6	30
34	Exploiting Protein Conformational Change to Optimize Adenosine-Derived Inhibitors of HSP70. Journal of Medicinal Chemistry, 2016, 59, 4625-4636.	6.4	29
35	Design and evaluation of 3,6-di(hetero)aryl imidazo[1,2-a]pyrazines as inhibitors of checkpoint and other kinases. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 4045-4049.	2.2	28
36	Diversity-Oriented Synthetic Strategies Applied to Cancer Chemical Biology and Drug Discovery. Molecules, 2014, 19, 17221-17255.	3.8	27

#	Article	IF	Citations
37	Targeted Small-Molecule Inhibitors of Protein Kinase B as Anticancer Agents. Anti-Cancer Agents in Medicinal Chemistry, 2009, 9, 32-50.	1.7	24
38	Synthesis and reactivity of 3-amino-1H-pyrazolo[4,3-c]pyridin-4(5H)-ones: development of a novel kinase-focussed library. Tetrahedron, 2010, 66, 2843-2854.	1.9	24
39	Multiparameter Lead Optimization to Give an Oral Checkpoint Kinase 1 (CHK1) Inhibitor Clinical Candidate: (R)-5-((4-((Morpholin-2-ylmethyl)amino)-5-(trifluoromethyl)pyridin-2-yl)amino)pyrazine-2-carbonitrile (CCT245737). Journal of Medicinal Chemistry, 2016, 59, 5221-5237.	6.4	24
40	A fragment-based approach applied to a highly flexible target: Insights and challenges towards the inhibition of HSP70 isoforms. Scientific Reports, 2016, 6, 34701.	3.3	24
41	Binding to an Unusual Inactive Kinase Conformation by Highly Selective Inhibitors of Inositol-Requiring Enzyme 1Î± Kinase-Endoribonuclease. Journal of Medicinal Chemistry, 2019, 62, 2447-2465.	6.4	23
42	Fragment-Based Screening Maps Inhibitor Interactions in the ATP-Binding Site of Checkpoint Kinase 2. PLoS ONE, 2013, 8, e65689.	2.5	23
43	Synthesis of 4-(cyclic dialkylamino)-7-azaindoles by microwave heating of 4-halo-7-azaindoles and cyclic secondary amines. Tetrahedron Letters, 2007, 48, 1527-1529.	1.4	20
44	Fragment-based screening identifies molecules targeting the substrate-binding ankyrin repeat domains of tankyrase. Scientific Reports, 2019, 9, 19130.	3.3	18
45	Multiple autophosphorylations significantly enhance the endoribonuclease activity of human inositol requiring enzyme 1Î±. BMC Biochemistry, 2014, 15, 3.	4.4	17
46	Design and synthesis of 2(1H)-pyrazinones as inhibitors of protein kinases. Tetrahedron, 2012, 68, 9713-9728.	1.9	16
47	Synthesis and evaluation of heteroaryl substituted diazaspirocycles as scaffolds to probe the ATP-binding site of protein kinases. Bioorganic and Medicinal Chemistry, 2013, 21, 5707-5724.	3.0	16
48	Divergent cyclisations of 2-(5-amino-4-carbamoyl-1H-pyrazol-3-yl)acetic acids with formyl and acetyl electrophiles. Tetrahedron, 2007, 63, 9627-9634.	1.9	14
49	Design and evaluation of 3-aminopyrazolopyridinone kinase inhibitors inspired by the natural product indirubin. Bioorganic and Medicinal Chemistry, 2011, 19, 3569-3578.	3.0	14
50	Identification of Autophosphorylation Inhibitors of the Inositol-Requiring Enzyme 1 Alpha (IRE1Î±) by High-Throughput Screening Using a DELFIA Assay. Journal of Biomolecular Screening, 2013, 18, 298-308.	2.6	13
51	An expedient synthesis of oxazepino and oxazocino quinazolines. Tetrahedron Letters, 2015, 56, 6478-6483.	1.4	13
52	Evolution of kinase polypharmacology across HSP90 drug discovery. Cell Chemical Biology, 2021, 28, 1433-1445.e3.	5.2	13
53	Identifying and Validating Tankyrase Binders and Substrates: A Candidate Approach. Methods in Molecular Biology, 2017, 1608, 445-473.	0.9	12
54	Fragment-Based Discovery of Inhibitors of Protein Kinase B. Current Topics in Medicinal Chemistry, 2009, 9, 1705-1717.	2.1	11

#	Article	IF	Citations
55	Synthesis and Evaluation of a 2,11â€Cembranoidâ€Inspired Library. Chemistry - A European Journal, 2016, 22, 5657-5664.	3.3	10
56	Labelled chemical probes for demonstrating direct target engagement in living systems. Future Medicinal Chemistry, 2019, 11, 1195-1224.	2.3	10
57	SimPLIT: Simplified Sample Preparation for Large-Scale Isobaric Tagging Proteomics. Journal of Proteome Research, 2022, 21, 1842-1856.	3.7	9
58	Fragment growing to retain or alter the selectivity of anchored kinase hinge-binding fragments. MedChemComm, 2014, 5, 180-185.	3.4	8
59	Modern Cancer Drug Discovery. , 2014, , 3-53.		8
60	A Mitsunobu reaction to functionalized cyclic and bicyclic N-arylamines. Tetrahedron Letters, 2018, 59, 238-242.	1.4	8
61	Solution NMR assignment of the ARC4 domain of human tankyrase 2. Biomolecular NMR Assignments, 2019, 13, 255-260.	0.8	7
62	Synthesis of a Riboseâ€Incorporating Medium Ring Scaffold via a Challenging Ringâ€Closing Metathesis Reaction. European Journal of Organic Chemistry, 2016, 2016, 4496-4507.	2.4	6
63	Modern cancer drug discovery: integrating targets, technologies and treatments. , 2008, , 3-38.		4
64	Genome-Protective Topoisomerase 2a-Dependent G2 Arrest Requires p53 in hTERT-Positive Cancer Cells. Cancer Research, 2022, 82, 1762-1773.	0.9	2
65	Discovery and Characterization of a Cryptic Secondary Binding Site in the Molecular Chaperone HSP70. Molecules, 2022, 27, 817.	3.8	1